Skip to main content

Lurasidone

ADVERTISEMENT
Identification
Molecular formula
C28H36N4O2S
CAS number
367514-87-2
IUPAC name
6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine
State
State

At room temperature, Lurasidone is typically found in a solid state as it is generally handled and distributed as a hydrochloride salt in the form of tablets for oral administration.

Melting point (Celsius)
237.50
Melting point (Kelvin)
510.60
Boiling point (Celsius)
518.80
Boiling point (Kelvin)
791.90
General information
Molecular weight
492.67g/mol
Molar mass
492.6670g/mol
Density
1.3730g/cm3
Appearence

Lurasidone hydrochloride typically appears as a white to off-white crystalline powder. It is often provided in tablet form for medical applications.

Comment on solubility

Solubility of 6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine

The solubility of 6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine can be influenced by several factors, including its molecular structure and the presence of functional groups. Generally, the solubility characteristics can be summarized as follows:

  • Polarity: The integration of a piperazine moiety tends to increase the polarity, potentially enhancing solubility in polar solvents.
  • Solvent Compatibility: This compound may exhibit better solubility in organic solvents such as dimethyl sulfoxide (DMSO) or ethanol rather than in water, due to its relatively large hydrophobic benzazepine structure.
  • Temperature Dependence: As with many organic compounds, solubility can increase with temperature, making it important to consider the temperature of the solvent.
  • pH Influence: The solubility may be affected by the pH of the solution, especially if the compound can ionize under certain conditions.

In conclusion, understanding the solubility profile of 6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine is essential for its applications in research and industry. It is crucial to conduct experimental solubility tests to determine the exact solubility limits in various media, which can provide insights into its behavior in pharmaceutical formulations and other practical applications.

Interesting facts

Interesting Facts about 6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine

The compound 6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine, often referred to in research contexts, exhibits a fascinating role in the field of medicinal chemistry. Here are some intriguing facts about this compound:

  • Pharmacological Potential: This compound has been studied for its potential applications in neuropharmacology, particularly in the context of neurodegenerative diseases and mood disorders. Its unique structural features may contribute to its ability to interact with specific neuroreceptors.
  • Structural Complexity: The compound contains a benzo[c][1]benzazepine core, a structure that is significant in many therapeutic agents. The addition of the piperazine ring enhances the compound’s solubility and bioavailability, which is crucial for drug design.
  • Medicinal Applications: Researchers are investigating this compound's ability to function as a serotonin receptor modulator. Enhanced understanding of its mechanism may lead to advancements in treatments for various psychological disorders.
  • Research Developments: Ongoing studies focus on synthesizing analogs of this compound to enhance its efficacy and reduce side effects. The exploration of structure-activity relationships (SAR) could provide deeper insights into optimizing its pharmacological properties.

Quote from a notable researcher: “The exploration of complex compounds like 6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine opens new pathways for innovative therapeutic strategies in psychiatry.”

This compound serves as a reminder of the intricate relationship between structure and function in drug design, emphasizing the ongoing need for interdisciplinary research in chemistry and medicine.

Synonyms
PERLAPINE
1977-11-3
Hypnodin
Perlapin
Perlapina
Perlapina [Spanish]
AW 14'2333
Perlapinum
Perlapinum [INN-Latin]
Perlapina [INN-Spanish]
6-(4-Methyl-1-piperazinyl)morphanthridine
AW-14'2333
4N8UJJ27IM
Hypnodin (TN)
Morphanthridine, 6-(4-methyl-1-piperazinyl)-
NSC-291840
DTXSID1048758
Perlapine [USAN:INN:BAN:JAN]
PERLAPINE [INN]
PERLAPINE [JAN]
PERLAPINE [MI]
PERLAPINE [USAN]
PERLAPINE [MART.]
NSC 291840
PERLAPINE [WHO-DD]
HF-2333
BRN 0434631
6-(4-methyl-1-piperazinyl)-11h-dibenz[b,e]azepine
6-(4-Methyl-1-piperazinyl)morfantridin
11H-Dibenz(b,e)azepine, 6-(4-methyl-1-piperazinyl)-
AW 142333
AW-142333
DTXCID8028684
6-(4-Methyl-1-piperazinyl)-11H-dibenz(b,e)azepine
Perlapinum (INN-Latin)
Perlapina (INN-Spanish)
PERLAPINE (MART.)
11H-Dibenz[b,e]azepine, 6-(4-methyl-1-piperazinyl)-
HUF-2333
PLP 100-127
6-(4-methylpiperazin-1-yl)-11H-dibenzazepine
Morphanthridine, 6-(4-methyl-1-piperazinyl)-(8CI)
811-429-5
NSC291840
6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine
CHEMBL340801
NCGC00182979-01
6-(4-Methylpiperazin-1-yl)-11H-dibenzo[b,e]azepine
MP-11
UNII-4N8UJJ27IM
Perlapine (JAN/USAN/INN)
SCHEMBL114768
CHEBI:31983
BAA97711
Tox21_113222
BDBM50102325
HB4889
PDSP1_000475
PDSP2_000473
AKOS027470205
NCGC00182979-02
CAS-1977-11-3
HY-110239
CS-0033103
NS00117936
11H-Dibenz[b, 6-(4-methyl-1-piperazinyl)-
D01438
WLN: T C676 IN BHJ J- AT6N DNTJ D1
L001286
6-(4-Methyl-1-piperazinyl)-11H-dibenzo[b,e]azepine
Q27260239
6-(4-Methyl-piperazin-1-yl)-11H-dibenzo[b,e]azepine
{11H-Dibenz[b,e]azepine,} 6-(4-methyl-1-piperazinyl)-
10-(4-methylpiperazin-1-yl)-9-azatricyclo[9.4.0.0?,?]pentadeca-1(15),3,5,7,9,11,13-heptaene